Full Text View
Tabular View
No Study Results Posted
Related Studies
A Relative Bioavailability Study of Alprazolam 3 mg Extended Release Tablets Under Non-Fasting Conditions
This study has been completed.
Study NCT00865657   Information provided by Actavis Inc.
First Received: March 18, 2009   No Changes Posted
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Healthy
Interventions listed in this trial
XANAX XR® 3 mg tablets, single dose
Additional drug interventions recognized in this trial
Alprazolam
More general drug interventions related to this trial
Anti-Anxiety Agents
Central Nervous System Agents
Central Nervous System Depressants
GABA Agents
GABA Modulators
Hypnotics and Sedatives
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Therapeutic Uses
Tranquilizing Agents
Sponsors listed in this trial
Actavis Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services